Page 3 - Pharma

Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025

806 applications approved so far under PLI schemes across 14 sectors

The government on Tuesday said as many as 806 applications have been approved under the Production Linked Incentive (PLI) schemes across 14 sectors as on date. The schemes for 14 key sectors including telecom, electronics, pharma, textiles and auto were announced with an outlay of Rs 1.97 lakh crore to enhance India's manufacturing capabilities and exports. It was announced in 2021. "As on date, 806 applications have been approved under PLI schemes across 14 sectors," Minister of State for Commerce and Industry Jitin Prasada said in a written reply to the Lok Sabha. He said that actual investment of Rs 1.76 lakh crore has been realised till March 2025 across 14 sectors, which has resulted in incremental production/sales of over Rs 16.5 lakh crore and employment generation of over 12 lakh (direct and indirect jobs). The pharmaceuticals sector has witnessed cumulative sales of Rs 2.66 lakh crore, which includes exports of Rs 1.70 lakh crore achieved in the first three years of the ..

Researchers map hair growth pathways for non-surgical hair restoration

The Esthetic Clinics and QR678 Research collaborate on groundbreaking research mapping hair growth pathways, potentially offering a non-surgical solution to hair restoration.

Wockhardt exits US generics biz, to focus on innovative portfolio

Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.

HC grants relief to Galderma against infringers using 'CETAPHIL' trademark

Bombay HC issues John Doe injunction allowing Galderma to take immediate action against counterfeit CETAPHIL products; seizures made in New Delhi and Mumbai

Lupin launches nasal spray in US, part of 200-drug pipeline by FY30

The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30

Emcure Pharma shares dip after 2.4% stake change hands in block trades

Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE

Biocon Biologics gets EU nod for two drugs to treat bone diseases

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, expanding its portfolio in bone disease treatment

Pharma industry rebuts Siddaramaiah's claims on Covid vax, heart attacks

The chief minister said the government was probing if Covid vaccines -- which were "hastily approved" during the pandemic -- could be among the reasons behind these incidents

Apollo Hospitals to list digital health, pharmacy unit in 18-21 months

The hospital operator will retain a 15 per cent stake in the entity, which it is yet to be named, and will also have its nominee on the board of the new company

New data shows just how powerful the next weight-loss drugs may be

The drugs in development include a pill that a new trial suggests is about as effective as Ozempic

BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus

CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine development to its alliance partner, Britain's GSK

OneSource eyes weight-loss drug boost to order book

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly

Pharma body seeks rethink on entry curbs of MRs in govt hospitals

Indian Pharmaceutical Alliance warns that the DGHS ban on medical representatives may affect public health, slow innovation and result in pharma sector job losses

Merck's potential cholesterol pill succeeds in late-stage studies

The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade

Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda

The partnership marks a strategic boost to Dr Reddy's oncology portfolio and expands Alvotech's biosimilar pipeline as Keytruda patents near expiry

Medical representatives barred from govt hospitals to stop pharma influence

The Centre's move seeks to curb the influence of pharmaceutical companies. Sharing of information must now happen through email or other digital platforms

Healthcare site Practo aims to double international revenue in 3 years: CEO

The company, which achieved profitability in the March 2024 quarter, was valued at $418 million as of April 2022, according to data from market intelligence platform Tracxn

Venus Remedies gets GMP renewal certification from Ukraine's SMDC

Pharma major Venus Remedies on Saturday said it has successfully renewed its good manufacturing practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement. "Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said. Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 .

Goyal criticises attempts to secure pharma patents via minor innovations

Commerce and Industry Minister Piyush Goyal on Sunday criticised attempts of certain firms to secure pharmaceutical patents through minor incremental innovations, stating that such practices could deprive millions from access to affordable medicines. Just for the "super-natural" profits of a few companies and their shareholders, the world has to suffer and is deprived of quality and equitable healthcare, he said. "I received requests very often that we should also allow pharmaceutical companies... to have incremental changes to their patents and allow them to have a fresh patent for another long period of time, which we normally understand that as evergreening of patents. "It is so sad that just for the profit of a few companies, just for the supernatural profits of a select few companies and possibly their shareholders, the world has to suffer," he said here at an event. Section 3(d) of the Indian Patents Act, 1970 restricts patents for already-known drugs unless the new claims ar